Starting Wegovy at 1mg: What the Third Step Really Means

Why 1mg sits where it does in the schedule

The Wegovy titration schedule exists because semaglutide's side effects (primarily nausea, constipation and digestive discomfort) are dose-dependent. Starting low and stepping up slowly gives the gut time to adapt. The standard path runs: 0.25mg for approximately four weeks, then 0.5mg for four weeks, and then 1mg for four weeks before the prescriber considers moving further. The starting-dose stage is purely about tolerability; by the time you reach 1mg, the question shifts slightly. The body is more settled, and the therapeutic signal (reduced appetite, slower gastric emptying, earlier feelings of fullness) tends to be clearer.

This is also the point in treatment where the experience becomes more individual. Some people find 1mg gives them a meaningful reduction in appetite and manage their eating more easily. Others feel the effect is partial and are keen to continue upward. Neither is unusual; it reflects normal variation in how people respond to semaglutide at a given dose, and it's precisely why a prescriber reviews your progress rather than a protocol ticking boxes automatically.

For a fuller picture of how every stage fits together, the complete Wegovy dosing overview sets out the schedule from 0.25mg to the 2.4mg (and now 7.2mg) maintenance doses with the clinical context behind each step. The NHS semaglutide patient page also covers what the medicine does and how it works in plain terms.

What the 1mg dose often feels like, and what side effects to be ready for

The most honest thing to say about 1mg is that the experience varies. Many people report that appetite feels noticeably quieter, smaller portions feel filling, interest in food between meals drops, and high-calorie cravings become easier to pass on. That's semaglutide working as intended.

Side effects at this dose follow the same pattern as earlier stages, just potentially more noticeable than at 0.5mg. Nausea is the most commonly reported symptom; it tends to be worst in the first few days after the injection and then eases. Constipation, loose stools, bloating and indigestion are also common. The clinical advice (eating smaller portions, avoiding fatty or very rich food, staying well hydrated) helps most people through the adjustment period. According to the NHS guidance on semaglutide, these gastrointestinal effects are the most frequently reported and are generally mild to moderate.

There are symptoms that need prompt medical attention rather than patient waiting. Severe, persistent stomach pain that spreads toward the back (with or without vomiting) should be assessed by a doctor urgently; this pattern can indicate pancreatitis, a known but uncommon side effect of GLP-1 medicines. Signs of a serious allergic reaction, gallbladder symptoms or signs of significant dehydration from prolonged vomiting or diarrhoea also warrant same-day medical contact. If anything feels wrong rather than just uncomfortable, reach out to a clinician. You can also report any suspected side effect through the MHRA's Yellow Card scheme.

The Wegovy treatment overview covers the broader side-effect picture across the full schedule if you'd like to read ahead.

The decision your prescriber is making at this point

Reaching 1mg isn't the end of a decision, it's the middle of one. After four or so weeks at this dose, the clinical question is: is it time to move to 1.7mg, stay longer at 1mg, or (in rare cases) step back? The answer depends on tolerability (whether side effects have settled enough to make an increase sensible), early response, and any other health factors in your picture.

The titration timeline in the Wegovy schedule is a guide, not a guarantee. A prescriber may recommend staying at 1mg for longer if nausea is still significant or if overall health circumstances have changed. Moving ahead too quickly tends to mean more side effects with less benefit; patience at each step is usually the better clinical call. Read about what changes at the 1.7mg stage to understand what comes next, and the 2.4mg maintenance dose if you're planning further ahead.

Private treatment through a regulated online pharmacy like nume follows the same clinical logic. A real prescriber (not an automated system) looks at where you are before each repeat is approved. Treatment is not issued on a subscription basis; each stage is clinically re-reviewed. When a pen is dispatched, it arrives by tracked DPD delivery in plain, unbranded packaging, usually the next working day.

If you're weighing up the cost of ongoing private treatment at this stage, the weight-loss treatment overview sets out what's included in the service price and what to compare when looking at different providers.

When to speak to your prescriber before the four weeks are up

The standard review point is around week four, but some situations call for contact before that. If side effects are severe enough to be affecting your daily life (if you can't keep food or fluids down, if pain is significant, if something feels out of the ordinary) don't wait for a scheduled review. Good aftercare means having somewhere to turn mid-cycle, not just at renewal time.

Questions our prescribers hear regularly at this stage: whether it's fine to delay the next injection by a day or two, what to do if the pen was stored incorrectly, whether supplements or other medications interact with semaglutide. These are questions for your prescriber and the Patient Information Leaflet, not a general guide. If you're already a patient with a question, the contact page connects you to our team seven days a week. For everything else, the FAQs page covers many of the questions patients bring to us most often. If you haven't yet started treatment and want a clinical assessment, you can speak to our prescribers through a free consultation.